Holen Sie sich die Stockscreener-App
16.67
1.37%
-0.25
Schlusskurs vom Vortag:
$16.92
Offen:
$16.93
24-Stunden-Volumen:
595.94K
Relative Volume:
0.82
Marktkapitalisierung:
$2.14B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-7.7341
EPS:
-2.1554
Netto-Cashflow:
-
1W Leistung:
-1.07%
1M Leistung:
+29.67%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.31
$17.33
1-Wochen-Bereich:
$16.18
$17.89
52-Wochen-Spanne:
$11.00
$18.18
Generate Biomedicines Inc Stock (GENB) Company Profile
Firmenname
Generate Biomedicines Inc
Sektor
Branche
Telefon
888-469-0055
Adresse
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
16.68 | 2.23B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
524.24 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.56 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.37 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.67 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Eingeleitet | Goldman | Buy |
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2026-03-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-24 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Generate Biomedicines Inc Aktie (GENB) Neueste Nachrichten
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
EBITDA of Generate Biomedicines, Inc. – BX:GENB - TradingView
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
GENBGenerate Biomedicines Inc Dividends - Finviz
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price to book forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to book forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Q&A: Generate Biomedicines CTO talks AI advancements - TechTarget
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Index - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Value Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 3000E Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 3000 Index - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS:GENB) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Generate Biomedicines stock ends week back above IPO price as volume jumps - TechStock²
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market - The Motley Fool
Transcript : Generate Biomedicines, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 03 - marketscreener.com
Enterprise value to EBITDA forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBIT forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBIT forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Actuals & Estimates (NASDAQ:GENB) - TradingView
Generate Biomedicines, Inc. Actuals & Estimates (BOATS:GENB) - TradingView
Price to sales forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Price to earnings forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
GENB Forecast — Price Target — Prediction for 2027 - TradingView
Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB) - Yahoo Finance
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts - Sahm
AdvanCell takes all of IQHQ’s 128,000-sq-ft Andover site - Stock Titan
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to S&P TMI Index - marketscreener.com
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Generate Biomedicines (GENB) Q1 2026 earnings summary - Quartr
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Generate Biomedicines (GENB) News Flow - Moomoo
Generate Biomedicines Surges 9.69%: Breaking Resistance Levels in Biotech RallyIntraday Trade Ideas - newsline.com
Generate Biomedicines (GENB) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Generate Biomedicines, Inc. (GENB) Market Cap - Zacks Investment Research
Generate Biomedicines (GENB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
GENB Price Today: Generate Biomedicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Why Is Generate Biomedicines, Inc. (GENB) Stock Down Today? - Meyka
Generate Biomedicines (GENB) Tumbles 7% as Selling Pressure Mounts – Key Support Levels in FocusSentiment Shift - newsline.com
Why Is Generate Biomedicines, Inc. (GENB) Stock Up Today? - Meyka
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains - Yahoo Finance
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x - simplywall.st
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Generate Biomedicines Inc. (GENB) Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue Development StageEarnings Analysis - newsline.com
Generate Biomedicines to Participate in Goldman Sachs Healthcare Conference on May 28, 2026 - geneonline.com
Finanzdaten der Generate Biomedicines Inc-Aktie (GENB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Generate Biomedicines Inc-Aktie (GENB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):